Guangdong Hengrui Pharmaceutical Co., Ltd

This study tests a new drug called SHR-1905 for adults with severe asthma that is not well controlled by current treatments. The goal is to see if it can reduce asthma attacks and improve breathing. About 408 participants will receive either the drug or a placebo, and researchers…

This study tests a new medicine called SHR-2173 for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 248 adults will receive either the drug or a placebo to see if it reduces disease activity without serious side effects. The main goal is…

This study tests an experimental drug called SHR-1819 in 200 adults with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it can reduce skin redness, itching, and rash. Participants will receive either the drug or a placebo injection, and researchers…

This study tests an experimental drug called SHR-1703 in 400 people aged 12 and older with eosinophilic asthma, a type often hard to control. Participants must already use daily inhaled steroids and another asthma medication. The goal is to see if the drug can reduce the number o…

This study tests a new drug, SHR-2173, in 75 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. The goal is to see if the drug can safely reduce protein in urine and improve kidney function. Participants will receive the injection and be m…

This study tests a new medicine called SHR-2173 in 10 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The main goal is to check safety and side effects. Participants will receive multiple injections, and d…

This study tests a new medicine called SHR-1703, given as multiple shots under the skin, to see if it is safe and helps control eosinophilic asthma over the long term. About 200 adults with asthma that is not well-controlled on standard inhalers will take part. The goal is to red…

This study tests a new medicine called SHR-1819 for teenagers aged 12 to 17 with severe eczema (atopic dermatitis). The goal is to see if the injection can reduce skin redness, itching, and rash better than a placebo. About 201 participants will receive either the drug or a dummy…

This study tests a new medicine called SHR-1703 for people with EGPA, a rare disease that causes inflamed blood vessels and organ damage. The goal is to see if the drug can help patients achieve remission and reduce their daily steroid dose. About 166 adults with relapsing or har…

This study tests an experimental drug called SHR-2173 for people with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can reduce protein in the urine and improve kidney function. About 51 adults with confirmed lupus and kidney inflam…

This study tests an experimental drug called SHR-1905 for adults with moderate-to-severe atopic dermatitis (a type of eczema). About 75 participants will receive either the drug or a placebo injection to see if it safely improves skin symptoms like redness and itching. The goal i…

This study tests an experimental drug called HRS-9813 in 270 adults with pulmonary fibrosis (IPF or PPF). The goal is to see if it can improve lung function and slow disease progression. Participants are randomly assigned to receive either the drug or a placebo, and neither they …

This study tests an experimental drug called SHR-1139 in 20 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. The trial has two parts: a 12-week induction phase to quickly reduce symptoms, followed by a 48-week maintenance…

This study tests an investigational injection called SHR-1819 in 100 adults aged 18 to 75 with seasonal allergic rhinitis (hay fever). The goal is to see if it reduces daily nasal symptoms like sneezing and congestion better than a placebo. Participants will receive the injection…

This study tests an experimental drug called SHR-1905 for people with long-term sinus inflammation and nasal polyps (growths in the nose). About 280 adults will receive either the drug or a placebo to see if it reduces polyp size and nasal congestion over 24 weeks. Participants m…

This early-stage study tests a new inhaled medicine called HRS-9821 in 160 people. First, healthy volunteers get a single dose to check safety. Then, people with COPD take multiple doses to see if it helps control their condition. The main goal is to find out if the drug is safe …

This study tests an experimental drug called SHR-1819 for adults with prurigo nodularis, a skin condition causing intense, persistent itching. The trial will compare the drug to a placebo to see if it safely reduces itch severity over 16 to 24 weeks. About 423 participants will r…

This early-stage study is testing a new drug called HRS-9813 in 20 healthy adults to see how it interacts with two existing medicines for pulmonary fibrosis (pirfenidone and nintedanib). The goal is to measure drug levels in the blood and check for side effects. This study does n…

This early-stage study tests a single injection of an experimental drug called SHR-3045 in 16 healthy adults aged 18-55. The main goal is to check for side effects and see how the drug moves through the body. This study does not aim to treat any disease; it is a first step to gat…